Skandinaviska Enskilda Banken (SEB)
VRDN icon

Skandinaviska Enskilda Banken (SEB)’s Viridian Therapeutics VRDN Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-286,320
Closed -$8.91M – 685
2025
Q4 		$8.91M Buy
+286,320
New +$7.85M 0.04% 304

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s VRDN Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 286,320 shares — an estimated $8.91M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in VRDN in Q4 2025 and held it in 1 quarter. The position peaked at $8.91M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 286,320 Viridian Therapeutics shares in Q1 2026, an estimated $8.91M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Viridian Therapeutics in Q4 2025 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Viridian Therapeutics position peaked at $8.91M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.